In a joint statement, the US Food and Drug Administration and the European Medicines Agency revealed yesterday (December 19) that they have initiated an initiative to share information on inspections of bioequivalence studies submitted in support of generic drug approvals.
This collaborative effort provides a mechanism to conduct joint facility inspections for generic drug applications submitted to both agencies, the two drug regulatory agencies stated.
Studies submitted for generic drug applications must demonstrate scientifically that a generic drug is “bioequivalent.” These studies help demonstrate that the generic drug performs in the same manner as the brand name drug. The FDA and the regulatory authorities in the European Union inspect facilities that conduct these studies to ensure data submitted to the agencies are reliable. Taking part in this initiative are the EMA and the European Union member states France, Germany, Italy, the Netherlands and the UK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze